FDA approves BMS's (BMY.US) lung cancer drug repotrectinib.
According to reports, the FDA has approved the drug repotrectinib from Roche for the treatment of a type of non-small cell lung cancer.
According to reports, the FDA has approved Bristol-Myers Squibb's drug repotrectinib for the treatment of a type of non-small cell lung cancer. Media reported later on Wednesday that the drug has been approved. The agency accepted BMS's repotrectinib application in May. The pharmaceutical company is seeking approval for the use of the drug in the treatment of advanced or metastatic ROS1-positive non-small cell lung cancer. In 2022, BMS acquired Turning Point Therapeutics for $4.1 billion, thereby gaining access to the repotrectinib therapy.
Related Articles
The trading volume of the market platform Polymarket has dropped for the first time in eight months, with technical malfunctions and increased competition pressure leading to a slowdown in growth.
US Stock Market Move | Bilibili, Inc. Sponsored ADR Class Z (BILI.US) rises more than 5%; daily video and podcast content viewing time breaks one billion minutes for the first time.
US Stock Market Move | Ford Motor Company (F.US) rose more than 8% as it enters the large-scale energy storage market with Contemporary Amperex Technology technology.
The trading volume of the market platform Polymarket has dropped for the first time in eight months, with technical malfunctions and increased competition pressure leading to a slowdown in growth.
US Stock Market Move | Bilibili, Inc. Sponsored ADR Class Z (BILI.US) rises more than 5%; daily video and podcast content viewing time breaks one billion minutes for the first time.
US Stock Market Move | Ford Motor Company (F.US) rose more than 8% as it enters the large-scale energy storage market with Contemporary Amperex Technology technology.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
